|ReShape Lifesciences -- USA Stock|| |
USD 2.05 0.07 3.54%
Co-Founder and VP of Clinical and Regulatory
Dr. Katherine S. Tweden, Ph.D., was promoted as Senior Vice President Research of the Company. She was the Vice President Clinical and Regulatory of EnteroMedics Inc., since May 2011. Prior to that Dr. Tweden served as our Vice President of Research and Clinical from September 2008 to May 2011 and our Vice President of Research from January 2003 to September 2008. From November 2002 to January 2003, Dr. Tweden was a consultant to Venturi Group, a medical device incubator company. From January 2003 through August 2004, Dr. Tweden worked for Venturi Development Inc. as a consultant to us. From July 1997 to October 2002, Dr. Tweden held positions including Director of Research and Vice President of Research for HeartStent Corporationrationration. From September 1990 to June 1997, Dr. Tweden held the positions of Senior Research Scientist and Principal Research Scientist at St. Jude Medical, Inc
Age: 53 Founder Since 2015
Tweden received a Bachelor of Arts in chemistry from Gustavus Adolphus College and a Master?s degree and Ph.D. in biomedical engineering from Iowa State University.
The company has return on total asset (ROA)
of (48.42) %
which means that it has lost $48.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (146.32) %
meaning that it created substantial loss on money invested by shareholders.
EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. ReShape Lifesciences (ETRM) is traded on Nasdaq Capital Markets in USA. It is located in St. Paul, MN and employs 37 people.
ReShape Lifesciences Leadership Team
|Jon Tremmel, CEO|
|Peter Delange, President|
|Scott Youngstrom, CFO|
|Dan Gladney, CEO|
|Nicholas Teti, Director|
|Carl Goldfischer, Director|
|Catherine Friedman, Director|
|Michael Mashaal, Director, Ph.D|
|Lori McDougal, Director|
|Gary Blackford, Director|
|Nick Ansari, President|
|Scott Shikora, President|
|Anthony Jansz, Director|
|Adrianus Donders, SVP|
|Katherine Tweden, Founder|
|Mark Knudson, Chairman, Ph.D|
|Gregory Lea, CFO|
|Paul Hickey, President|
|Bobby Griffin, Director|
|Tonya Dowd, President|
|Naqeeb Ansari, President|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on ReShape Lifesciences. What is your perspective on investing in ReShape Lifesciences? Are you bullish or bearish?
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1)
For any level of risk, select the one which has the highest expected return. 2)
For any expected return, select the one which has the lowest volatility.